Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Flortaucipir→

Flortaucipir Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1415379-56-4
Molecular formula
C16H10FN3
Molecular weight
263.27 g/mol
Drug class
Diagnostic radiopharmaceuticaltau positron-emission tomography (PET) imaging agent
Mechanism of action
A fluorine-18-labelled tracer that binds to aggregated tau neurofibrillary tangles in the brain. The spatial distribution and density of retained tracer are assessed by PET imaging.
Indications / reported uses
  • PET imaging to estimate the density and distribution of aggregated tau neurofibrillary tangles in adults with cognitive impairment who are being evaluated for Alzheimer’s disease; it is an adjunct to other diagnostic evaluations.

Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212123Orig1s004lbl.pdf · https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212123s000lbl.pdf

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Flortaucipir Environmental Risk Assessment (ERA) (the Flortaucipir ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.